ArticleJournal of translational medicine2006
Molecular signatures induced by interleukin-2 on peripheral blood mononuclear cells and T cell subsets.
Article in Journal of translational medicine, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 49 citations in OpenAlex.
- Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection.Genome biology · 2007Trial
- DNA-directed assembly of multivalent lipid nanoparticles for targeted T cell gene delivery.Journal of controlled release : official journal of the Controlled Release Society · 2026Article
- Cytokine landscape in hospitalized children with multisystem inflammatory syndrome.Scientific reports · 2024Article
- IL-2Rα-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25Nature cancer · 2023Article
- Effect of Systemic Administration of CD4Comparative medicine · 2023Article
- Article
- Non-invasive image-based cytometry for high throughput NK cell cytolysis analysis.Journal of immunological methods · 2021Article
- T cell receptor sequencing in autoimmunity.Journal of life sciences (Westlake Village, Calif.) · 2020Article
- Genetic contribution of suppressor of cytokine signalling polymorphisms to the susceptibility to infection after traumatic injury.Clinical and experimental immunology · 2018Article
- Pharmacokinetic properties of radiolabeled mutant Interleukin-2v: a PET imaging study.Oncotarget · 2018Article
- Characterization of porcine cytokine inducible SH2-containing protein gene and its association with piglet diarrhea traits.Asian-Australasian journal of animal sciences · 2017Article
- Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance.The Journal of experimental medicine · 2015Article
- Therapeutic effect of lymphokine-activated killer cells treated with low-dose ionizing radiation on osteosarcoma.Oncology letters · 2015Article
- CD28-inducible transcription factor DEC1 is required for efficient autoreactive CD4+ T cell response.The Journal of experimental medicine · 2013Article
- The role of E3 ubiquitin ligase Cbl proteins in interleukin-2-induced Jurkat T-cell activation.BioMed research international · 2013Article
- Association of CISH -292A/T genetic variant with hepatitis B virus infection.Immunogenetics · 2012Article
- Molecular insights on the peripheral and intratumoral effects of systemic high-dose rIL-2 (aldesleukin) administration for the treatment of metastatic melanoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2011Article
- CISH and susceptibility to infectious diseases.The New England journal of medicine · 2010Article
- Molecular immune signatures of HIV-1 vaccines in human PBMCs.FEBS letters · 2009Article
- Systemic treatment of xenografts with vaccinia virus GLV-1h68 reveals the immunologic facet of oncolytic therapy.BMC genomics · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
Abstract
Experimentally, interleukin-2 (IL-2) exerts complex immunological functions promoting the proliferation, survival and activation of T cells on one hand and inducing immune regulatory mechanisms on the other. This complexity results from a cross talk among immune cells which sways the effects of IL-2 according to the experimental or clinical condition tested. Recombinant IL-2 (rIL-2) stimulation of peripheral blood mononuclear cells (PBMC) from 47 donors of different genetic background induced generalized T cell activation and anti-apoptotic effects. Most effects were dependent upon interactions among immune cells. Specialized functions of CD4 and CD8 T cells were less dependent upon and often dampened by the presence of other PBMC populations. In particular, cytotoxic T cell effector function was variably affected with a component strictly dependent upon the direct stimulation of CD8 T cells in the absence of other PBMC. This observation may provide a roadmap for the interpretation of the discrepant biological activities of rIL-2 observed in distinct pathological conditions or treatment modalities.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.